A double-blind, double dummy, randomized, parallel group, multi-center, phase III study to evaluate the efficacy and safety of TAK-475 [lapaquistat] alone and TAK-475 administered in combination with ezetimibe versus ezetimibe alone in subjects with primary dyslipidemia.

Trial Profile

A double-blind, double dummy, randomized, parallel group, multi-center, phase III study to evaluate the efficacy and safety of TAK-475 [lapaquistat] alone and TAK-475 administered in combination with ezetimibe versus ezetimibe alone in subjects with primary dyslipidemia.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Ezetimibe; Lapaquistat
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Mar 2008 Status changed from in progress to discontinued. According to a Takeda media release, development of lapaquistat is being discontinued.
    • 07 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top